| [1] |
Rinella ME, Lazarus JV, Ratziu V, et al. A multisociety Delphi consensus statement on new fatty liver disease nomenclature [J]. J Hepatol, 2023, 79(6): 1542-1556
|
| [2] |
Powell EE, Wong V, Lindor K. Non-alcoholic fatty liver disease [J]. Lancet, 2021, 397(10291): 2212-2224.
|
| [3] |
Tilg H, Adolph TE. Role of dietary factors in the pathogenesis of nonalcoholic fatty liver disease [J]. Nat Rev Gastroenterol Hepatol, 2024, 21(1): 55-70.
|
| [4] |
Lee J, Vali Y, Boursier J, et al. Accuracy of noninvasive tests to detect advanced fibrosis in metabolic dysfunction-associated fatty liver disease: systematic review and meta-analysis [J]. Clin Gastroenterol Hepatol, 2024, 22(2): 255-267.e9.
|
| [5] |
Yan D, Wang J, Jiang F, et al. The monocyte-to-high-density lipoprotein cholesterol ratio is associated with the severity of metabolic associated fatty liver disease and fibrosis [J]. Diabetes Metab Syndr Obes, 2022, 15: 995-1005.
|
| [6] |
Feingold KR. The bidirectional relationship between HDL and inflammation [J]. Metabolism, 2023, 148: 155690.
|
| [7] |
Arroyo-jiménez MM, Cardenas J, LóPEZ-CILLEROS S, et al. Inflammation in metabolic associated fatty liver disease: Mechanisms and therapeutic targets [J]. Biomed Pharmacother, 2023, 166: 115375.
|
| [8] |
Mineo C, et al. HDL as a modulator of inflammation: Implications for atherosclerosis [J]. J Clin Invest;129(10): 4021-4024.
|
| [9] |
Wang S, Zhou Y, Zhang Y, et al. Association between monocyte-to-high-density lipoprotein cholesterol ratio and nonalcoholic fatty liver disease: A cross-sectional study [J]. Medicine, 2021, 100(18): e25764.
|
| [10] |
Liu Q, Cook MB. Statistical methods for evaluating the potential for heterogeneity of treatment effect in clinical trials [J]. Curr Epidemiol Rep, 2020, 7(3): 104-111.
|
| [11] |
Chen Y, Zhang X, Pan X, et al. Nonlinear associations of anthropometric indices with metabolic dysfunction-associated fatty liver disease: A large-scale cross-sectional study [J]. Hepatol Int, 2023, 17(5): 1237-1248.
|
| [12] |
Zhang X, Wu M, Zhou Y, et al. Association of lymphocyte-to-high-density lipoprotein ratio with prevalence of non-alcoholic fatty liver disease: a cross-sectional study [J]. BMC Gastroentero, 2023, 23(1): 71.
|
| [13] |
Desbouvries L, Levis B, Benedetti A. Evaluation of non-linear associations between prognostic factors and outcomes in observational studies: A practical guide using restricted cubic splines [J]. J Clin Epidemiol, 2023,159: 86-95.
|
| [14] |
Li X, Zhang X, Liu Y, et al. Threshold effects and nonlinear associations between serum uric acid and metabolic dysfunction-associated fatty liver disease in the US population [J]. Front Endocrinol, 2023, 14: 1226897.
|
| [15] |
Kim D, Kim WR, Kim HJ, et al. Association between anthropometric indices and metabolic dysfunction-associated fatty liver disease: A nationwide cross-sectional study [J]. Clin Gastroenterol Hepatol, 2022, 20(6): e1187-e1196.
|
| [16] |
Liu Z, Zhang Y, Graham S, et al. Causal relationships between NAFLD and cardiometabolic risk factors: A Mendelian randomization study [J]. Hepatology, 2022, 76(5): 1382-1394.
|
| [17] |
Rinella ME, Tianoch FD, Caldwell SH, et al. Guidance for the clinical application of the new nomenclature for metabolic dysfunction-associated fatty liver disease [J]. Hepatol Commun, 2023, 7(7): e0178.
|
| [18] |
European Association for the Study of the Liver (EASL), European Association for the Study of Diabetes (EASD), European Association for the Study of Obesity (EASO). EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease [J]. J Hepatol, 2016, 64(6): 1388-1402.
|
| [19] |
Harrell FEJR. Regression modeling strategies: with applications to linear models, logistic and ordinal regression, and survival analysis [M]. 2nd ed. Cham: Springer, 2020.
|
| [20] |
Vanderweele TJ, Knox D. Statistical methods for studying the heterogeneity of treatment effects across levels of a second variable [J]. Epidemiol Methods, 2023, 12(1): 20220012.
|
| [21] |
Liu W, Baker RD, Baker SS. The complex interplay between obesity, metabolic dysfunction, and inflammation in the pathogenesis of nonalcoholic fatty liver disease [J]. Children, 2022, 9(7): 1009.
|
| [22] |
Liu J, Ayada I, Zhang X, et al. Estimating global prevalence of metabolic dysfunction-associated fatty liver disease in overweight or obese adults [J]. Clin Gastroenterol Hepatol, 2022, 20(3): e573-e582.
|
| [23] |
Wang Y, Vos MB, Rimasch DL, et al. Saturation kinetics in metabolic pathways: Implications for disease progression [J]. Trends Endocrinol Metab, 2021, 32(9): 659-671.
|
| [24] |
Liu S, Li Y. Understanding saturation effects in biological systems: From molecules to populations [J]. Biophys Rev, 2020, 12(4): 821-831.
|
| [25] |
Kazankov K, Jørgensen SMD, Thomsen K L, et al. The role of macrophages in nonalcoholic fatty liver disease and nonalcoholic steatohepatitis [J]. Nat Rev Gastroenterol Hepatol, 2019, 16(3): 145-159.
|
| [26] |
Masuda Y, Kanda T, Kagawa T, et al. Recent insights into the role of autophagy in nonalcoholic fatty liver disease [J]. Int J Mol Sci, 2023, 24(3): 2699.
|
| [27] |
Byrne CD, Targher G. NAFLD: a multisystem disease [J]. J Hepatol, 2015, 62(1S): S47-S64.
|
| [28] |
Sokolovic M, Djordjevic A, Stefanovic A, et al. Oxidative stress and inflammation in the pathogenesis of nonalcoholic fatty liver disease [J]. Antioxidants, 2023, 12(4): 869.
|
| [29] |
Richardson TG, Hemani G, Perry JRB, et al. Collider bias and the apparent protective effect of obesity on mortality in observational studies [J]. Int J Epidemiol, 2024, 53(1): dyad158.
|
| [30] |
Kawano Y, Cohen DE. Mechanisms of hepatic triglyceride accumulation in non-alcoholic fatty liver disease [J]. J Gastroenterol, 2023, 58(6): 525-539.
|
| [31] |
Kolb H, Martin S. Environmental/lifestyle factors in the pathogenesis and prevention of type 2 diabetes [J]. BMC Med, 2017, 15(1): 131.
|
| [32] |
Liu Y, Zhou D. The complexity of inflammation in metabolic associated fatty liver disease: Beyond simple biomarkers [J]. Front Immunol, 2023, 14: 1174628.
|
| [33] |
Zhou Y, Ou X, Zhang J, et al. Value of the lymphocyte-to-high-density lipoprotein cholesterol ratio for predicting metabolic-associated fatty liver disease in a Chinese population[J]. Diabetes Metab Syndr Obes, 2022, 15: 221-230.
|
| [34] |
Wang L, et al. Association between lymphocyte-to-HDL-C ratio and hyperuricemia in postmenopausal women [J]. Nutr Metab Cardiovasc Dis, 2021, 31(7): 2204-2211.
|
| [35] |
Park C, Nguyen P, Hernandez C, et al. Magnetic resonance imaging as a biomarker in nonalcoholic fatty liver disease [J]. Hepatology, 2023, 77(4): 1331-1346.
|
| [36] |
Vilana R, Forn X, Arcia-mon C, et al. Limitations of ultrasound in the assessment of liver fibrosis in nonalcoholic fatty liver disease [J]. World J Gastroenterol, 2022, 28(1): 106-119.
|
| [37] |
Vilgrain V, Ronot M, Di Martino M, et al. Current role of imaging in non-alcoholic fatty liver disease [J]. World J Gastroenterol, 2021, 27(22): 3017-3029.
|
| [38] |
Angulo P, Kleiner DE, Damsgard S, et al. Development and validation of a simple NAFLD clinical scoring system for identifying patients without advanced disease [J]. Gut, 2023, 72(7): 1355-1362.
|
| [39] |
Younossi ZM, Paigan L, Henry L, et al. Epidemiology of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: Implications for liver transplantation [J]. Transplantation, 2023, 107(1): 45-53.
|